Secondary glioblastoma is a rare brain tumor characterized by a mutation in isocitrate dehydrogenase, which is reported to lead to epigenetic modification. Patients with secondary glioblastoma experience poor survival and quality-of-life outcomes due to the disease's aggressiveness and a lack of targeted therapies. In this report, a patient with a secondary glioblastoma was treated with a histone deacetylase inhibitor, an epigenetic drug with potent anti-inflammatory properties, in addition to the standard regimen. The patient showed very favorable survival and quality-of-life measures, and a restoration of several neuro-metabolites as measured by spectroscopic magnetic resonance imaging.
CITATION STYLE
Gurbani, S. S., Weinberg, B. D., Salgado, E., Voloschin, A., Velazquez Vega, J. E., Olson, J. J., … Shim, H. (2020). Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor. Oxford Medical Case Reports, 2020(3), 87–90. https://doi.org/10.1093/omcr/omaa006
Mendeley helps you to discover research relevant for your work.